Author's response to reviews

Title: Safety and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor YN968D1 in Patients with Advanced Malignancies

Authors:

Jin Li (fudanlijin@163.com)
Xinmin Zhao (mizuyi@hotmail.com)
Lei Chen (chenlei350401@sohu.com)
Haiyi Guo (guohaiyi-sh@hotmail.com)
Fangfang Lv (lvff80@yahoo.com)
Ka Jia (fudanjiaka@163.com)
Ke Yv (yuk@mail.shcnc.ac.cn)
Fengqing Wang (wfg@mail.shcnc.ac.cn)
Chuan Li (chli@mail.shcnc.ac.cn)
Jun Qian (junqian68@hotmail.com)

Version: 5 Date: 24 September 2010

Author's response to reviews: see over
Dear Editor,

We have made the formatting changes as requested for the manuscript titled “Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies” (Journal: BMC Cancer MS ID : 4133455573803329) as below:

1. The Author list has been re-written using the required style and order.
2. The trial registration number has been added to the abstract.
3. “Conclusions” has been added after the discussion.
4. The section of Authors’ contributions has been added and all authors have read and approved the final manuscript.
5. The tables have been included in the manuscript so that it is visible within the final published manuscript.
6. Format of References has been changed.
7. Format of the title has been changed.
8. The “introduction” section has been renamed “background”.
9. The “Conflict of interest statement” has been renamed “Competing interests”
10. The references has been revised to contain all authors’ names for each citation and the term “et al.” has been deleted.
11. The legends of the figure have been included within the manuscript after the reference list.

The manuscript has been proofread and all changes were made
accordingly.

Thank you for your time.

Yours sincerely,

Jin Li